Education
About Us
Working with TipRanks
Follow Us
Rigel Pharmaceuticals (RIGL)
:RIGL
RIGL Stock Chart & Stats
$29.97
-$0.99(-5.79%)
At close: 4:00 PM EST
$29.97
-$0.99(-5.79%)
Day’s Range― - ―
52-Week Range$13.57 - $43.72
Previous CloseN/A
Volume99.93K
Average Volume (3M)598.54K
Market Cap
$527.18M
Enterprise Value$292.84M
Total Cash (Recent Filing)$108.38M
Total Debt (Recent Filing)$61.04M
Price to Earnings (P/E)5.5
Beta2.17
Next Earnings
Nov 06, 2025EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.28
Shares Outstanding17,937,340
10 Day Avg. Volume436,580
30 Day Avg. Volume598,542
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue1.09
Enterprise Value/Gross Profit1.19
Enterprise Value/Ebitda2.68
Forecast
1Y Price Target
$42.50Price Target Upside41.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe first patient has been enrolled into the dose expansion phase of the Phase 1b R289 study, marking an important step in R289's development.
Regulatory EngagementRigel plans to engage with the FDA to discuss a potential registrational pathway for R289, which should provide valuable clarity on the next steps for the program.
Revenue GrowthTavalisse delivers record growth and contributes to a strong total revenue performance.
Bears Say
Clinical Trial RisksFactors that could impede reaching the price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding.
Rigel News
RIGL FAQ
What was Rigel Pharmaceuticals’s price range in the past 12 months?
Rigel Pharmaceuticals lowest stock price was $13.57 and its highest was $43.72 in the past 12 months.
What is Rigel Pharmaceuticals’s market cap?
Rigel Pharmaceuticals’s market cap is $527.18M.
When is Rigel Pharmaceuticals’s upcoming earnings report date?
Rigel Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 11 days.
How were Rigel Pharmaceuticals’s earnings last quarter?
Rigel Pharmaceuticals released its earnings results on Aug 05, 2025. The company reported $3.28 earnings per share for the quarter, beating the consensus estimate of $2.58 by $0.7.
Is Rigel Pharmaceuticals overvalued?
According to Wall Street analysts Rigel Pharmaceuticals’s price is currently Undervalued.
Does Rigel Pharmaceuticals pay dividends?
Rigel Pharmaceuticals does not currently pay dividends.
What is Rigel Pharmaceuticals’s EPS estimate?
Rigel Pharmaceuticals’s EPS estimate is 0.9.
How many shares outstanding does Rigel Pharmaceuticals have?
Rigel Pharmaceuticals has 17,937,340 shares outstanding.
What happened to Rigel Pharmaceuticals’s price movement after its last earnings report?
Rigel Pharmaceuticals reported an EPS of $3.28 in its last earnings report, beating expectations of $2.58. Following the earnings report the stock price went up 22.979%.
Which hedge fund is a major shareholder of Rigel Pharmaceuticals?
Currently, no hedge funds are holding shares in RIGL
Rigel Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.50 (41.81% Upside)
$42.50 (41.81% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.1%
Last 30 Days ▲ 24.4%
Last 30 Days ▲ 24.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
107.69%
12-Months-Change
Fundamentals
Return on Equity
376.09%
Trailing 12-Months
Asset Growth
61.00%
Trailing 12-Months
Company Description
Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. (RIGL) is a biotechnology company focused on the discovery and development of innovative therapies for patients with rare diseases and cancer. The company operates primarily in the biopharmaceutical sector and is known for its targeted treatments that leverage its expertise in small-molecule drug development. Rigel's core products include medications that address hematologic disorders and oncology, with a focus on advancing its pipeline of candidates through various stages of clinical trials.
RIGL Company Deck
RIGL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was overwhelmingly positive, highlighting significant sales growth across all products, increased revenue guidance, strong financial performance, and successful market expansion strategies. While there was a minor reevaluation in patient responder data, it did not significantly detract from the overall positive performance and outlook for the company.View all RIGL earnings summariesRIGL Stock 12 Month Forecast
Average Price Target
$42.50
▲(41.81% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Verastem
―
RegenXBio
―
Bicycle Therapeutics
―
Opthea Limited Sponsored ADR
―
Ownership Overview
2.60% Insiders
27.81% Mutual Funds
0.28% Other Institutional Investors
54.35% Public Companies and
Individual Investors